Dave, your explanation sounds more like jealousy than

New Post Public Reply Private Reply Replies (1) Message Board
Warp Daveludlow #18601
Dave, your explanation sounds more like jealousy than critical thinking. The management advantage of being awarded options occurs in every public company. It is a sweet deal, and it encourages them to run the company well and to be successful. Options are worthless if the company doesn't succeed. If our management team achieves $2 share price in the market, they win, and any shareholder who still holds shares wins... well, maybe not so much for the guy who buys at $1.90 on the way up.

I disagree that someone who paid for their shares with cash has any more at risk than someone who was awarded options. Look at John Commissiong. He owns 20M shares. He hasn't purchased shares in the secondary market since the company was formed, but you have no idea how much of his own or Gerald's money went into the formation of this company. There's a reason they were awarded shares from day one. John's life's work is in this company. For you to suggest they have less at risk than the average retail investor is ridiculously self serving and misguided.
Quote:
These top management don't care about short term problems with the stock. They know in 10 years they will be kazillionaires.
Bad argument. Seriously bad. One, it's impossible for management to know this, just as it is for retail investors. They may believe it, and if they do, they buy shares, just as our CEO and CFO and many other shareholders have done. Let me ask you this, Dave. If you could buy a winning lottery ticket right now, but you had to wait 5-10 years for the payout, would you buy it? Tickets cost $20K each, and you are allowed to buy multiple tickets. How many would you buy? Would you take on a second job just for the opportunity of buying more of these tickets? Or are you one of these people who look at the PowerBall $10M starting jackpot (after someone won $300M last week) and remark, "$10M isn't worth me buying a ticket." Or perhaps you decline because of the missed "opportunity costs" of having to wait 5-10 years. That kind of reasoning baffles me.

I dont agree with your statement that management doesn't care about short term problems. One of management's concerns is shareholder sentiment. But their focus is on long term value and success of the company, and value for the long-term shareholders. They aren't going to make business decisions to satisfy the short-term speculator or trader.
Quote:
But for those who invested based on Gerald's statements and guidance, this has been a very disappointing year. And if your time frame is more in the 2 to 3 year range.....then this becomes an even bigger disappointment. Many speculators chose AMBS over other stocks that have gone up much more over the past year. (Opportunity Costs) So they consider this past 1.5 years as a bust. But not for you, apparently.
If your investment time frame here was in the 2 to 3 year range when you invested, then you're not an investor, and certainly not a long-term investor as you claim. You're a speculator. It never ceases to amaze me how many "investors" get confused over this. Go to any financial planner who has the CFP certification (not easy to get and signifies they actually know what they're talking about) and ask them about investing in stocks. They'll tell you that you should only invest in equities with an outlook of 5 years or longer, because in the short term, stocks are volatile and you may lose money if you need to sell. They'll tell you to only invest money you can leave alone for the long term. They'll tell you it's not smart to invest your emergency fund in stocks, or even in mutual funds. But we continue to see people doing these dumb things and calling themselves investors instead of speculators. There's a reason an extremely high percentage of day traders lose money overall. They are speculators and this entails extreme risk. If you invested in a pre-revenue biotech company with a 2 to 3 year time frame believing it was an investment, then you're the fool. It's not management's job to make you money. It's their job to manage the company and build it into a world leader biotech company. If your expectation of that happening is 2 to 3 years from your investment point, you're delusional. All of the critical thinking in the world won't help you. Maybe you should have a glass of the Kool Aid, not the stuff you've been drinking all this time.

Amarantus Bioscience Holdings (AMBS) Stock Research Links

AMBS Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

OSV Talks Launches New Season on Ministry Growth

Updated Category News Views 5

A Fresh Wave of Ideas for Catholic Ministry Some topics never go out of style, and it looks like the crew at OSV is banking on that with their latest salvo of OSV Talks. With themes ranging from peacemaking to AI, they're tossing it all against the spiritual wall, hoping it sticks. The comeback of their video series has that classic 'get your act together' vibe we all...

Continue Reading
Laredo Oil Eyes Big Gains in Argentina's Oil Play

Updated Category News Views 6

Argentina's Oil Play: Laredo Oil's Bold Venture Talk about shooting for the stars. Laredo Oil's second tête-à-tête with Santa Cruz Province's big wigs highlights their itch to rejuvenate Argentina's tired oil fields. For folks who know the nitty-gritty of oil, we're talking about the Golfo San Jorge Basin, a place where old dogs might learn new tricks thanks to that...

Continue Reading
Bryan Cranston Stars in Live Streaming 'A Christmas Carol'

Updated Category News Views 10

Cranston Climbs Into Scrooge's Shoes for a Cause If you think you've got the holiday season all figured out, add this curveball: Bryan Cranston as Ebenezer Scrooge, jawing through "A Christmas Carol" as part of a unique, one-night-only staged reading. And it's not just another star-studded ploy for attention. It's about rallying around a cause bigger than holiday cheer,...

Continue Reading
NSSF Battles NM's Unconstitutional Gun Law in Court

Updated Category News Views 10

Taking Shots at New Mexico's Gun Laws You've got the National Shooting Sports Foundation (NSSF) heading back into the legal trenches. Fresh lawsuit filed, they're targeting New Mexico's Attorney General, Raúl Torrez, for trying to keep a seven-day "cooling off" period intact that they've already been told is unconstitutional. Look, this ain't their first rodeo with this...

Continue Reading
IBM Backs Leena AI: Shaping Enterprise Automation

Updated Category News Views 10

IBM's Strategic Bet on Enterprise Automation Diving into the blazing 2026 market, IBM Ventures has thrown its weight behind Leena AI, an enterprise agentic AI firm that's out to shake things up. You see, the name of the game isn't just flashy AI chatbots anymore. Companies like Leena AI are setting their sights on the back-office grunt work—the lifeblood operations in...

Continue Reading
FAA Greenlights Boeing’s 737-10: What’s at Stake?

Updated Category News Views 5

Breaking New Ground: Boeing 737-10 Certified Well, the folks at Boeing must be popping champagne, because the U.S. Federal Aviation Administration (FAA) just handed them the golden ticket: certification for the brand spankin' new Boeing 737-10. This ain't your average paper-pushing approval. We're talking nearly 1,000 test flights and what seems like a mountain of safety...

Continue Reading
Fitch Ratings Applauds Ecopetrol's Financial Sturdiness

Updated Category News Views 3

Ecopetrol: A Rock in Turbulent Waters If you’re looking for a boulder in a sea of pebbles, Ecopetrol’s got the heft. When Fitch Ratings gives a thumbs-up, you best believe they mean it. On October 20, 2026, the rating agency confirmed Ecopetrol’s global credit rating at BB, with a stable outlook, but it’s how they got there that counts. Their standalone credit...

Continue Reading
Jackson Hewitt Aims to Recruit 15,000 Seasonal Staff

Updated Category News Views 8

Revving Up for Tax Season: Jackson Hewitt's Hiring Push When tax season looms, the hustle can't be understated, and Jackson Hewitt is cranking it up by hunting for 15,000 new recruits to tackle this annual financial circus. Starting October 26, this hiring fest is open season across the nation, pulling out all the stops to bolster its workforce. But what does this mean...

Continue Reading
NEXT Properties' Exchange Offer Sees Strong Participation

Updated Category News Views 3

NEXT Properties Makes Bold Moves with Exchange Offers NEXT Properties has pulled the trigger on a massive swap of its notes, and it's a tale investors should tune into. They're swapping out their old notes like a veteran trader ditching penny stocks for blue chips. It’s an intriguing maneuver—risk-laden yet foreboding to anyone who knows the game. Breaking Down the...

Continue Reading
S?LACE Boats Unveils First Catamaran, the 41CT

Updated Category News Views 4

Setting a New Course with the 41CT Picture this: a company known for pushing the envelope does it again, but this time, they aren't just elbowing their way into the catamaran market—they're redefining it. S?LACE Boats has unveiled their all-new 41CT center console catamaran. Not just another addition, it's practically a game-changer for anyone passionate about offshore...

Continue Reading

Top 5 Most Recently Viewed Articles

Pfizer and Eli Lilly: Discovering Value in Pharma Stocks

Updated Category News Views 137

Valuations in the biopharma sector hit wild swings, dragging investors to hunt for bargains. Back in the day, Pfizer was riding high on booming revenues, but that turned into a horror show as its trailing twelve-month operating income dropped to $1.3 billion—a staggering 94% plunge over three years. The culprit? A nosedive in sales from COVID-19 products and...

Continue Reading
Graco Inc. Announces Substantial Quarterly Dividend Boost

Updated Category News Views 133

Graco Inc. Increases Dividend for Shareholders Graco Inc. has made a significant announcement regarding its quarterly dividend policies that enthusiastic investors should take note of. Recently, the Board of Directors declared a quarterly dividend increase of 7.8 percent, bringing the total to 27.5 cents (or $0.275) per common share. This marks a major move for the...

Continue Reading
ParaZero's Revolutionary Airdrop System Gains Global Approval

Updated Category News Views 155

ParaZero Secures Global Marketing Approval for DropAir System ParaZero Technologies Ltd. (Nasdaq: PRZO) is on an exciting path of growth as it emphatically strides into new markets. The company, based in Israel, has recently announced that it has received official marketing approval from the Israeli Ministry of Defense for its innovative DropAir Precision Airdrop System....

Continue Reading
Nautilus Biotechnology Prepares for Third Quarter 2025 Results

Updated Category News Views 138

Nautilus Biotechnology Plans Q3 2025 Financial Results Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a pioneering company focused on single-molecule protein analysis, is set to announce its third quarter financial results. This report is scheduled for release before market opening on Tuesday. Webcast Conference Call to Discuss Financial Results The management team of...

Continue Reading
Bluebird Bio's Acquisition: What Investors Need to Know

Updated Category News Views 166

Understanding Bluebird Bio's Recent Acquisition Bluebird Bio, Inc. BLUE has recently made headlines after entering into a definitive agreement to be acquired by prominent global investment firms Carlyle Group Inc. CG and SK Capital Partners. This development is pivotal for Bluebird, a company focused on gene therapy, which seeks to address rare genetic diseases. Financi

Continue Reading